SNX-2112, Catalog: B2211

Alternate Names 2-[(trans-4-Hydroxycyclohexyl)amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]benzamide; PF-04928473

Appearance Crystalline solid

CAS # 908112-43-6

Molecular Formula C₂₃H₂₇F₃N₄O₃

Molecular Weight 464.48

Purity ≥ 98% by HPLC

Solubility DMSO (>50 mg/ml)

SMILES CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)O)C(F)(F)F)C

InChi InChI=1S/C23H27F3N4O3/c1-22(2)10-17-19(18(32)11-22)20(23(24,25)26)29-30(17)13-5-8-15(21(27)33)16(9-13)28-12-3-6-14(31)7-4-12/h5,8-9,12,14,28,31H,3-4,6-7,10-11H2,1-2H3,(H2,27,33)

InChi Key ZFVRYNYOPQZKDG-UHFFFAOYSA-N

PubChem CID 24772860

Storage Conditions -20°C

Shipping Conditions Gel Pack

USAGE For Research Use Only! Not For Use in Humans.

Handling Do not take it internally. Wear a glove and mask when handling the product. Protect from air and moisture.

SNX-2112 is a potent heat-shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. SNX-2112 selectively accumulates in tumors compared to normal tissues and binds to the N-terminal adenosine triphosphate binding site of Hsp90, inhibiting its activity. This results in the proteasomal degradation of oncogenic client proteins, which prevents signaling through these client proteins, induces apoptosis and inhibits tumor cell proliferation.